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Abstract
The anti-diabetic drug metformin regulates T-cell responses to immune activation and is proposed to function by regulating
the energy-stress-sensing adenosine-monophosphate-activated protein kinase (AMPK). However, the molecular details of
how metformin controls T cell immune responses have not been studied nor is there any direct evidence that metformin
acts on T cells via AMPK. Here, we report that metformin regulates cell growth and proliferation of antigen-activated T cells
by modulating the metabolic reprogramming that is required for effector T cell differentiation. Metformin thus inhibits the
mammalian target of rapamycin complex I signalling pathway and prevents the expression of the transcription factors c-
Myc and hypoxia-inducible factor 1 alpha. However, the inhibitory effects of metformin on T cells did not depend on the
expression of AMPK in T cells. Accordingly, experiments with metformin inform about the importance of metabolic
reprogramming for T cell immune responses but do not inform about the importance of AMPK.
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Introduction
T lymphocytes respond to pathogens by differentiating to
effector subpopulations that mediate the protective immune
response. Effector T cells strikingly increase their cellular uptake
of multiple nutrients including glucose, amino acids and transfer-
rin. They also swap from metabolising glucose primarily through
oxidative phosphorylation to become highly glycolytic [1–4]. The
changes in effector T cell metabolism are important as judged by
the consequences of inhibiting key metabolic regulators. For
example, the serine/threonine kinase mTORC1 (mammalian
Target Of Rapamycin Complex 1) integrates inputs from
nutrients, antigen and cytokine receptors to link T cell metabolism
and T cell differentiation [5]. mTORC1 thus controls expression
of cytolytic effector molecules, chemokine and adhesion receptors
in effector T cells [3,6] and controls effector-memory cell
transition [7,8].
One other regulator of T cell differentiation is the adenosine-
monophosphate (AMP)-activated protein kinase (AMPK) [9,10].
AMPK is phosphorylated and activated by liver kinase B1 (LKB1)
in response to energy stress and functions to enforce quiescence to
restore energy balance in cells [11]. In T lymphocytes, AMPK is
important for the transition of effector T lymphocytes to memory
T cells during the contraction phase of the immune response [10].
Hence as inflammatory signals fade during the resolution of
immune responses, signalling via AMPK allows T effector cells to
resume a metabolically quiescent state so that they persist to
produce accelerated responses upon secondary infection [10].
The idea that AMPK is an important regulator of T cell
functions has been strengthened by the observations that
metformin, a drug that activates AMPK, inhibits the production
of effector T lymphocytes and promotes the production of memory
T cells [12–14]. The anti-inflammatory actions of metformin
extend to its ability to suppress the development of autoimmune
diseases in mouse models [12,15]. Moreover, metformin has been
shown to inhibit the proliferation and survival of acute myeloid
leukaemic [16] and T-cell acute lymphoblastic leukaemic cells
[17,18].
Metformin activates AMPK because this drug inhibits respira-
tory chain complex I and thereby causes an increase in the cellular
AMP/ATP ratio [19], leading to the phosphorylation and
activation of AMPK via LKB1 [11]. The effects of metformin
on T cell function are thus invariably interpreted in terms of its
ability to activate AMPK. Indeed, current models of AMPK
function in immune cells are based largely on experiments with
metformin. There is, however, a critical caveat because metformin
only indirectly activates AMPK, because it inhibits respiratory
chain complex I and thereby causes an increase in cellular AMP/
ATP ratio. Metformin thus has many effects on cell metabolism
that are not mediated by AMPK [20–22]. Indeed, even the actions
of metformin in the liver that underpin its efficacy in the treatment
of diabetes have been shown to be AMPK-independent [20,22].
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The potential for AMPK-independent actions of metformin
does not seem to be considered in any of the immunological
studies that use this drug to manipulate cellular immune responses.
Consequently, the regulatory effects of metformin in the immune
system are used to model the role of AMPK. Accordingly, the
objective of the present study is to explore the relevance of AMPK
in mediating the immune-regulatory effects of metformin in T
lymphocytes. We compared the effects of metformin on antigen
receptor and cytokine regulated responses in wild type and
AMPKa1null CD8 T cells. We found that metformin controls key
metabolic pathways in T cells and hence controls T cell growth
and proliferation. However, the immune regulatory effects of
metformin have no requirement for expression of AMPK in T
cells. Experiments with metformin thus inform about the
importance of metabolic signalling for T cell biology but do not
inform about the role of AMPK.
Materials and Methods
Ethics Statement
Mice, OT-I TCR+ transgenic or AMPKa1fl/fl CD4Cre+, were
bred and maintained under specific pathogen-free conditions in
the Biological Resource Unit at the University of Dundee. The
procedures used were approved by the University Ethical Review
Committee, a committee of the University Court, at its meeting on
19th December 2007 and subsequently authorised by a project
licence according to the UK Home Office Animals (Scientific
Procedures) Act 1986 as issued by the Home Office on 14th April
2008.
Lymphocyte Culture
CD8pos lymphocytes were isolated by autoMACS using the
CD8a+ T cell Isolation Kit II (Miltenyi Biotec, Germany). CTL
cultures from OT-I TCR+ mice were generated as previously
described [3,10,23]. Where outlined, cultures were also treated
with 10 mM metformin (1,1-dimethylbiguanide hydrochloride;
Sigma-Aldrich). Where shown, freshly isolated lymphocyte
cultures were maintained in 5 ng mL21 IL-7 (Peprotech) for
indicated periods of time. For proliferation assays, lymph node
suspensions from OT-I TCR+ mice were labelled with 5 mM
CFSE or Cell Tracer Violet (Molecular Probes) and TCR
activated with 1 nM SIINFEKL in the absence or presence of
10 mM metformin for up to 72 h.
Immunoblotting
Lymphocytes were lysed in F buffer (16107 cells mL21) and
subjected to immunoblot analysis as described previously [3,10].
Total ACC and ACCS79 were detected by bi-fluorometric analysis
using the Odyssey LICOR system and ImageJ software was used
for integral signal quantification. Anti-AMPKa1 and anti-ACCS79
were kindly provided by Grahame Hardie, University of Dundee,
U.K. Anti-Smc1 was purchased from Bethyl Laboratories Inc and
anti-Hif1a was obtained from R&D Systems. Anti-Glut1 was a gift
from Geoff Holman, University of Bath, U.K. [19,24]. All other
antibodies for immunoblotting were obtained from Cell Signaling
Technology. Antigens were detected using suitable HRP-conju-
gated secondary antibodies and enhanced chemoluminescence.
Flow Cytometry
Accurate cell counts of lymphocyte cultures were taken by using
AccuCheck counting beads (Life Technologies, UK) or, alterna-
tively, by direct event counts against volumetric flow rate on
FACSVerse (Beckton Dickinson). Antibodies used for flow
cytometry were conjugated to fluorescein-isothiocyanate (FITC),
phycoerythrin (PE), peridinin-chlorophyll protein (PerCP)-Cy.5.5,
PE-Cy7, allophycocyanin (APC), APC-eFluor 780 or Alexa Fluor
647 and were obtained from BD Pharmingen or eBiosciences
unless otherwise stated: anti-CD8a (clone 53-6.7), anti-CD25
(clone PC61), anti-CD44 (clone IM7), anti-CD69 (clone H1.2F3),
CD71 (clone C2), CD98 (clone RL388; Biolegend). Intracellular
levels of S6 protein phosphorylated on S235 and S236 (S6S235/6)
were detected by using Alexa-Fluor-647-conjugated anti-S6S235/6
(4851; Cell Signalling Technologies) as previously described [23].
Following incubation with antibodies, cells were washed and re-
suspended in FACS buffer. Samples were analysed using LSR II
Fortessa or FACSVerse (Becton Dickinson). A minimum of 16104
ungated events were acquired and stored. Data files were
processed using the FlowJo software V9.6.4 (Treestar) for Mac
OS. Live cells were gated according to their forward and side
scatters.
Metabolic Assays
Glucose uptake and lactate output assays were performed as
previously described [3,23].
Statistical Analysis
Quantified data were statistically evaluated using non-paramet-
ric Mann-Whitney test or two-way ANOVA with Bonferroni’s
comparisons test, where specified. Bar graphs were drawn as mean
6 standard deviation (SD). GraphPad Prism 6 for Mac OS X was
used for statistical analysis and generation of bar graphs of
quantified data.
Results and Discussion
Metformin regulates glucose uptake and mTORC1
activity in T cells
To understand the effects of metformin on T cells, CD8+ OT-I
TCR+ T cells were activated by the T cell antigen receptor (TCR)
ligand SIINFEKL in the absence or presence of 10 mM
metformin. T cells respond to antigen receptor triggering by up-
regulating expression of the adhesion molecule CD69 and up-
regulating expression of CD98, a key subunit of System L amino
acid transporters (Figure 1A). Antigen activated T cells exposed
to metformin also up-regulated expression of CD69 and CD98
and their response was comparable to that of control antigen
receptor activated T cells (Figure 1A). Metformin treated T cells
also respond to TCR engagement by increasing expression of the
interleukin-2 receptor (IL-2R) a chain CD25 and the hyaluronan
adhesion receptor CD44 (Figure 1A). However metformin
treatment caused a modest decrease in the expression of these
receptors compared to the normal response of antigen activated T
cells (Figure 1A). Moreover, a striking effect was that metformin-
treated T cells did not undergo normal blastogenesis in response to
TCR engagement (Figure 1B).
T cells respond to antigen by increasing glucose uptake and by
making a switch from oxidative phosphorylation to aerobic
glycolysis [3,25,26]. Metformin-treated antigen receptor activated
T cells showed reduced glucose uptake but increased lactate
output compared to control antigen-activated cells (Figure 1C
and D). In T cells, glucose uptake is mediated by the glucose
transporter Glut1, whose expression is regulated by the transcrip-
tion factors c-Myc and hypoxia-inducible factor-1a (HIF-1a)
[3,25]. Metformin treatment blocked TCR-induced expression of
c-Myc, HIF-1a and Glut1 (Figure 1E). We also examined the
impact of metformin on the activity of mTORC1 in TCR-
activated T cells. mTORC1 activity was monitored by assessing
the phosphorylation of the mTORC1 substrate sequence in p70
AMPK-Independent Actions of Metformin in T Cells
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S6-Kinase 1 (p70S6K1T389) and phosphorylation of the S6K
substrate sequence in the S6 ribosomal subunit (S6S235/6).
Figure 1E shows that metformin treatment inhibited TCR-
induced phosphorylation of p70S6KT389 and S6S235/6. Metfor-
min-treated cells also expressed lower levels of S6 protein,
suggesting that metformin also decreased TCR-induced ribosomal
biogenesis (Figure 1E). One other key metabolic change that
normally accompanies T cell activation is the induction of
Figure 1. Metformin controls TCR-induced blastogenesis, metabolic reprogramming and mTORC1 signalling in CD8 T cells. Whole
lymph node suspensions from OT-I TCR+ mice were incubated with IL-7 or activated with ovalbumin-derived SIINFEKL [1 nM] in the absence or
presence of 10 mM metformin for 20 h. CD8pos cells were analysed by flow cytometry (A) for TCR-induced changes in the surface expression of CD25
(interleukin-2 receptor a chain), CD44 (hyaluronan adhesion receptor), CD69 (early T cell activation) and CD98 (heavy chain of the system L
transporter) and (B) for changes in cell size using forward and side scatter (FSC and SSC, respectively). (C, D) TCR-activated CD8pos T cells were
purified by negative selection and then cultured for 3–4 h and subjected to (C) radio-labelled glucose ([3H] 2-DG) uptake or (D) lactic acid production
assays. Bar graphs display pooled data from three independent mice in triplicate analysis and show mean 6 SD. Statistical analysis was Mann-
Whitney test, where **p,0.01 and ***p,0.001. (E) Purified CD8pos T cells from IL-7-treated or TCR-activated lymph nodes were rested in conditioned
medium (that is medium retained from IL-7-treated or TCR-activated whole lymph node culture) for 3–4 h and then lysed at 16107 cells mL21 for
subsequent immunoblot analysis of indicated phospho- and pan-proteins. Immunoblots are representative of two independent mice. (F) CD8pos cells
were analysed for the expression of CD71 (transferrin receptor) following TCR activation for 20 h. Bi-parametric plots and histograms are
representative of at least three independent experiments.
doi:10.1371/journal.pone.0106710.g001
AMPK-Independent Actions of Metformin in T Cells
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expression of the transferrin receptor CD71. Figure 1F shows
that TCR-induced up-regulation of CD71 was severely reduced in
cells treated with metformin compared to control antigen receptor
activated cells.
AMPK-independent actions of metformin in T cells
The actions of metformin on lymphocytes are interpreted to
reflect the impact of this drug on AMPK [13]. To directly examine
the role of AMPK as the effector of metformin, we compared the
effects of metformin on wild type versus AMPK-null T cells. T
Figure 2. Metformin effects on metabolism and proliferation are independent of AMPK in T cell effectors. (A) Cell suspensions of
lymph nodes from AMPKa1fl/fl or AMPKa1fl/fl CD4-Cre+ mice bearing the OT-I TCR were activated with 1 nM SIINFEKL and treated as described in
Figure 1A. CD8pos cells were analysed by flow cytometry for TCR-induced changes in cell size using forward and side scatter (FSC and SSC,
respectively). (B) Lymph node cells from AMPKa1fl/fl or AMPKa1fl/fl CD4-Crepos mice bearing OT-I TCR were labelled with CFSE or Cell Tracer Violet,
respectively, and mixed in a one-to-one-ratio. Co-cultures were then activated with 1 nM SIINFEKL for up to 72 h in the absence or presence of
10 mM metformin. CD8pos cells were analysed for proliferation-induced dilution of loaded fluorescent dyes using flow cytometry. Data are
representative of three independent experiments. (C) In-vitro-generated AMPKa1fl/fl or AMPKa1fl/fl CD4-Crepos CTL were treated without or with
metformin [10 mM] for 48 h. The starting cell number was 26105. Proliferation was assessed over the period of treatment by cell counts using flow
cytometry. Bar graph displays pooled data of four independent culture experiments. Two-way ANOVA with Bonferroni’s multiple comparisons test
was used to determine statistical differences with **p,0.01 and ***p,0.001 between treatments. (D) One million IL-2-differentiated AMPKa1fl/fl and
AMPKa1fl/fl CD4Crepos CTL were cultured in absence or presence of metformin [10 mM] for 48 h and subjected to [3H] 2-DG uptake or lactic acid
production assays. Bar graphs display pooled data of three independent mice analysed in triplicate and are mean 6 SD.
doi:10.1371/journal.pone.0106710.g002
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cells only express the AMPKa1 catalytic isoform [10,27].
Accordingly, we could study the role of AMPK as a mediator of
metformin actions using isolated AMPKa1 null T cells from mice
with a T cell selective deletion of AMPKa1 (CD4Cre+ AMPKa1fl/
fl (AMPKa1null) mice) [10,28]. The data in Figure 2 show that
metformin blocked T cell blastogenesis and proliferation in both
wild type and AMPKa1null naı¨ve TCR-triggered T cells
(Figure 2A and B). Hence, the ability of metformin to block T
cell growth and proliferation is not mediated by AMPK.
In further experiments, we compared the effects of metformin
on IL-2 induced growth and proliferation of AMPKa1-sufficient
and -deficient cytotoxic T cells (CTL). IL-2 controls effector T cell
differentiation and antigen-receptor-activated CD8 T cells cul-
tured in IL-2 clonally expand and differentiate to CTL [29]. The
rationale for looking at the effects of metformin on IL-2 signalling
in CTL is that these cells have high rates of glucose uptake and are
highly glycolytic and it is not clear if they would show any
sensitivity to metformin, which inhibits cellular metabolism
through the inhibition of respiratory chain complex I. Moreover,
IL-2 is a key pro-inflammatory cytokine for effector CTL
differentiation in vivo [29] and hence understanding the impact
of metformin on IL-2 responses in T cells might give insights as to
why this drug can modify effector/memory T cell differentiation
in vivo. Figure 2C addresses this issue and shows that metformin
inhibits IL-2-induced clonal expansion of CTL. Moreover, the
inhibitory effects of metformin were comparable in AMPKa1-
sufficient and -deficient CTL.
Metformin did not inhibit glucose uptake by CTL but
significantly increased lactate output of CTL in a response that
was not dependent on the expression of AMPKa1 in CTL
(Figure 2D). We have shown previously that AMPKa1 can
function to terminate mTORC1 activity in CTL under conditions
of energy stress [10]. Figure 3 shows that control and
AMPKa1null CTL had high levels of mTORC1 activity as
Figure 3. Metformin blocks mTORC1 signalling independent of AMPK in lymphoblasts. CTLs differentiated in IL-2 were treated without or
with metformin [10 mM] for 48 h. Protein extracts (16107 cells mL21) were subject to immunoblot analysis for indicated phospho- and pan-proteins.
(A) Changes in mTORC1 signalling were assessed by the phosphorylation levels of S6K on T389, T421/S424 and S6 on S235/6 and S240/4. S6K and S6
proteins were used as loading control for equal number of cells between conditions. Molecular weight markers in kD are shown to the right of
immunoblot panels. (B) Intracellular S6S235/6 in CTL left untreated, treated with metformin [10 mM] or rapamycin [20 nM]. Data are representative of
at least three independent experiments. (C) Activation of AMPK was assessed by induction of phosphorylation of acetyl-CoA carboxylase (pACC/ACC)
on S79 and AMPK on T172. Anti-AMPKa1 was used to show successful deletion of AMPK function in T cells. SMC1 and GSK3 were used as total
loading control. Molecular weight markers are shown to the right of immunoblot panels. Ratio of pACC/ACC was determined by signal detection
using the Licor Odyssey system and quantified by signal integration using ImageJ software. Bar graph and immunoblots shown are representative of
at least two independent experiments.
doi:10.1371/journal.pone.0106710.g003
AMPK-Independent Actions of Metformin in T Cells
PLOS ONE | www.plosone.org 5 September 2014 | Volume 9 | Issue 9 | e106710
assessed by the levels of IL-2-dependent phosphorylation of
p70S6K on T389 and T421/S424, S6S235/6 and S6S240/4.
Strikingly, metformin inhibited mTORC1 signalling equally in
AMPKa1-sufficient and -deficient CTL (Figure 3A). Further, we
have assessed levels of S6S235/6 in control and AMPKnull CTL
upon metformin treatment using flow cytometry providing a
means of measuring indirectly metformin effects on mTORC1
signalling and compared this with the treatment of CTL using the
mTORC1 inhibitor rapamycin. The data in Figure 3B reveal
that metformin treatment decreased S6S235/6 phosphorylation
equally in control and AMPKnull CTL and to a comparable effect
as rapamycin treatment of CTL. Hence, although metformin
could activate AMPK in T cells (Figure 3C), AMPKa1 does not
mediate the inhibitory actions of metformin on mTORC1 activity
in T cells.
Conclusion
The present study shows that metformin has direct effects on T
cells to block their blastogenesis and proliferation. Metformin acts
to suppress these T cell responses, because it blocks key metabolic
changes triggered by engagement of the T cell antigen receptor
complex. Metformin was also able to supress the proliferative
response induced by the cytokine IL-2 in effector cytotoxic T cells.
Metformin-treated antigen receptor activated T cells have
complex metabolic defects and fail to increase glucose uptake or
express transferrin receptors. This effect of metformin on T cell
metabolism could be explained in part by its effect on mTORC1
activity [3] but could also reflect that metformin-treated T cells
cannot respond to T cell activation to normally express the
transcription factors c-Myc and HIF-1a. These are key transcrip-
tion factors that control the expression of nutrient transporters in
T cells [3,25].
It has been shown that metformin treatment can promote
memory T cell responses [13] and it was assumed that the
immune-modulatory actions of metformin reflected the role of
AMPK in memory T cells. Indeed, subsequent studies showed that
AMPK is required for the formation of CD8 memory T cells as it
restrains mTORC1 activity under conditions of glucose energy
stress [10]. Nevertheless, despite the reciprocal effects of metfor-
min treatment and AMPK deletion on memory T cell responses
there has been no direct assessment of the role of AMPK as a
mediator of metformin action in T cells. The current study
addresses this issue and shows that metformin has potent effects as
an immunosuppressant independently of AMPK. The present
results thus afford the insight that experiments with metformin
inform about the importance of metabolic signalling for T cell
biology but do not inform about the role of AMPK. How does
metformin exert its immune-modulatory actions if not via AMPK?
In this context, the direct target for metformin is respiratory chain
complex I. It is known that naı¨ve T cells are dependent on
oxidative phosphorylation for ATP generation and hence the
sensitivity of these cells to metformin would reflect this. It was
intriguing that the present data show that effector CTL, cells that
are highly glycolytic, were also sensitive to metformin. Thus,
although the immune activation of T cells is associated with a
switch to glycolysis, the present results argue that metabolic
pathways channelled via respiratory chain complex I are
important for both naı¨ve and effector T cells.
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